PREDICTMEDIX AI INC - PMEDF STOCK NEWS

Predictmedix Inc. has secured a revenue-generating deployment of its Safe Entry Stations at the DeBeers Forevermark Forum 2022, taking place from June 29 - July 1, 2022. This deployment is part of an ongoing partnership with Entertainment Bay, aimed at enhancing health safety protocols at live events. The stations screen for signs of infectious diseases, including COVID-19. CEO Dr. Rahul Kushwah expressed optimism about increased interest from event organizers, indicating potential future deployments.

Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announced its fiscal 2022 results, reporting revenues of $134,820 with a gross profit of $84,820 (63% margin), driven by the scaling of its Safe Entry Station technology. The company achieved a net loss of $1.9 million for the year, compared to a net loss of $1.6 million in 2021. Significant milestones include receiving CE Mark and ISO13485 certification, enabling commercialization in the EU, and initiating a clinical study to enhance its FDA Class II Medical Device application.

Predictmedix Inc. (CSE: PMED)(OTCQB: PMEDF) announced that Interim CEO Dr. Rahul Kushwah will present at the 12th Annual LD Micro Invitational in California on June 7, 2022. The presentation is scheduled for 11:00 a.m. Pacific time at the Four Seasons, followed by one-on-one investor meetings. Predictmedix specializes in rapid health screening solutions powered by AI, offering tools to analyze physiological data and identify health issues, including infectious diseases. For more information, visit www.Predictmedix.com.

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) successfully deployed its Safe Entry Station at a major Las Vegas event, demonstrating its rapid health screening technology.

The partnership with Uptown Sports Marketing allowed the Company to showcase its AI-enabled screening solution, evaluating staff and performers for infectious diseases, including COVID-19. Dr. Rahul Kushwah noted the opportunity to engage with numerous hospitality representatives, emphasizing Las Vegas' potential as a deployment market due to its high visitor volume. The Safe Entry Station aims to enhance public health safety.

Predictmedix (CSE:PMED)(OTCQB:PMEDF) shares key milestones in a letter from Interim CEO Dr. Rahul Kushwah, highlighting 2021 as a transformative year. The company's major achievements include the deployment of Safe Entry Stations at high-profile events, receiving CE Mark and ISO13485 certification, and enhancing technology with Edge Computing for quicker screening. Initial commercialization efforts are underway, supported by strategic partnerships. Predictmedix aims to position itself as a leader in health screening solutions and plans to advance R&D, targeting FDA certification for its technology in 2022.

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has announced a clinical study set to begin in February 2022 at a North American hospital, aimed at validating its AI-driven Infectious Diseases Detection Solution. The study will utilize the company's Safe Entry Stations to screen staff and incoming patients for infectious diseases, including COVID-19. This step is crucial for FDA Class II medical device certification and commercial launch. Results will be published in a peer-reviewed journal. The study aims to enhance the AI algorithms and data collection, supporting the company's expansion in healthcare.

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) announced the results of a study on its AI technology for detecting alcohol and cannabis impairment, showing efficacy rates of 79-87% and 76-92% respectively. The company plans a clinical trial in February 2022 at a North American hospital to validate these findings further. The AI system is designed to be contactless, cost-effective, and capable of immediate results. Predictmedix is also seeking classification of its technology as a class II medical device in the US.

Predictmedix Inc. (CSE: PMED, OTCQB: PMEDF) announced the first placement of its Safe Entry Station at Ste. Anne's Spa in Ontario, enhancing health and safety for staff and guests. This collaboration with partners Juiceworks Exhibits and SBL Testing Technologies highlights Predictmedix's entry into the hospitality sector as demand for safe experiences rises amid ongoing COVID-19 challenges. The Safe Entry Station is designed to identify symptoms of infectious diseases, adding a crucial layer of safety in public spaces.

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) announced the successful launch of the ThuraPass Safe Entry Program at the 2021 Formula One United States Grand Prix. This program employs rapid AI-powered health screening technology to identify COVID-19 symptoms among event staff and attendees. During its first major deployment, over 400,000 people attended the event, and several staff members were flagged and sent home for recovery. The screening process takes about three seconds, enhancing safety in enclosed hospitality areas. This initiative aims to provide risk mitigation as indoor events resume.